The call ran from 9:01 AM to 10:04 AM IST (1 h 3 min).
Key takeaways
Metropolis delivered a robust 16% revenue growth, beating prior 12-13% organic guidance. Operating leverage is kicking in, with H1 margins expanding 190 bps despite heavy monsoon headwinds and no price hikes.
| Revenue: guided vs achieved | 16.00% achieved Guided 12.00%–13.00%, 23.1% above the top of the range; confirmed by management |
|---|---|
| EBITDA Margin guidance | 1.7% → 1.9% Raised by 0.2 percentage points |
| Management target | Revenue 16.0% FY27 |
| Revenue growth | 16% YoY growth, exceeding historical 12-13% organic trend. |
|---|---|
| Margins | EBITDA margin expanded 180 bps YoY to 27.2% in Q2. |
| Demand visibility | Strong; structural shift toward organized players and chronic disease management. |
| Management confidence | High; emphasizing operational efficiency and high-end specialty testing dominance. |
Growth
Revenue grew 16% YoY, driven by 10% patient volume and 11% test volume increases. B2C and specialty segments saw high-teens growth.
Outlook
EBITDA margins guided to expand 125-170 bps for FY27; price hike planned for Q4 FY27.
Risks
Pricing revisions planned for Q4 could impact volumes if competitors don't follow; initial M&A integration typically sees margin dips.
Last quarter's promises, checked
Delivered
- Rev growth guided 14-15% ex-price/M&A → 16% (= BEAT)
- Specialty to outgrow total → specialty +20% vs 16% total (= BEAT)
- EBITDA margin 27-28% in 2-3 yrs from 24.4% → 27.2% in Q2 (= BEAT)
Partly delivered
- 100 mini-hubs in ~2 yrs, 50 in Y1 → no hub count disclosed; only Insta 60 home-visit launch (= PARTIAL)
Missed
- 250-300 centres added per qtr → 116 new centres (= MISS)
Summary by ALFA Finder, written with AI assistance from our own recording of the call, published . Open it on ALFA Filings ›
The results behind this call
Metropolis Healthcare Q2 FY27 Results: Net Profit ₹75.5 Cr, Up 42.7% YoY
Metropolis Healthcare Ltd reported revenue from operations of ₹496.8 Cr (+15.8% YoY) and net profit of ₹75.5 Cr (+42.7% YoY) for Q2 FY27.
- Key figure
- Net profit ₹75.5 Cr · +42.7% YoY
What management said last time
Full summary →From the call summary published .
Outlook they gave
Management guides for 14-15% revenue growth and 27-28% EBITDA margins over the next two years.
Growth they described
Revenue grew 17% YoY, primarily driven by a 10% increase in patient volumes rather than price hikes.
Call details
| Company | Metropolis Healthcare Ltd |
|---|---|
| NSE symbol | METROPOLIS |
| ISIN | INE112L01020 |
| Call | Q2 FY27 earnings call |
| Date | Wednesday, 4 November 2026 |
| Time | 9:00 AM IST |
| Length | 1 h 3 min |
| Audio | Our stream on YouTube ↗ |
Metropolis Healthcare Ltd: key numbers
- Share price
- ₹575.00
- Market cap
- ₹11,929 Cr
- Revenue (annual)
- ₹1,646 Cr
- Net profit (annual)
- ₹190.0 Cr
- P/E (TTM)
- 53.2×Sector 53.8×
- Promoter holding
- 47.82%-1.04% QoQ
- FII holding
- 11.67%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Other calls on Wed, 4 Nov
Today's concalls →
